Skip to main content
Premium Trial:

Request an Annual Quote

Big Pharma's Got One Toe In, At Least

At VentureBeat, David Hamilton points to news reported in the New York Times of the establishment of the International Serious Adverse Events Consortium. The consortium consists of seven big pharma companies, each of which will contribute funds to research into developing genetic tests to determine which patients are at risk from dangerous drug side effects. According to Hamilton, it’s good that “one of the first major industry-wide personalized medicine efforts should focus specifically on rare side effects, since it is exactly these sorts of safety problems that pose the biggest threat to the blockbuster-drug model in the first place.” However, he’s not sure if this means that big pharma is ready to buy into personalized medicine wholesale.


The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.